Propanc Biopharma, Inc. (PPCB) Reports Preclinical PDAC Data; Plans Phase 1b in Q1 2027

Propanc Biopharma (PPCB) aims to begin patient screening for its cancer treatment PPC-001 in February 2027. The Phase 1b study will involve up to 50 patients with solid tumors in Australia. The company is finalizing clinical protocols and site assessments, with regulatory submissions planned for early 2027. PPC-001 has received FDA Orphan Drug Designation for pancreatic cancer.

Propanc Biopharma (NASDAQ:PPCB) reported preclinical data for its pancreatic cancer treatment PRP, showing reduced cell proliferation, migration, and invasion in chemoresistant models. The study, conducted with Spanish universities, also showed upregulation of E-cadherin and EPCAM, and downregulation of Vimentin and Snail. PRP has FDA Orphan Drug Designation and a Phase 1b trial is planned for Q1 2027.

Propanc Biopharma reported preclinical data suggesting its PRP formulation may re-sensitize chemotherapy-resistant pancreatic cancer cells. The company plans a Phase 1b trial in Q1 2027.

Propanc Biopharma (NASDAQ:PPCB) published a peer-reviewed study in Scientific Reports on its pancreatic proenzyme combination PRP, showing anti-tumor efficacy in lab and animal models, and improved survival in human patients. The study evaluated PRP's impact on 24 cancer cell lines, with significant tumor weight reduction and no adverse events reported. The company is developing PRP for pancreatic, ovarian, and refractory prostate cancers.

Propanc Biopharma (PPCB) reported preclinical data for PRP, showing over 90% tumor growth inhibition and extended survival in pancreatic cancer models. PRP, with FDA Orphan Drug Designation, targets cancer biology aspects beyond RAS mutations. The company plans a Phase 1b trial in Q1 2027. PPCB stock closed at $0.49, up 1.51%.

Propanc Biopharma (Nasdaq: PPCB) reported preclinical data showing its lead candidate PRP achieved over 90% tumor growth inhibition in pancreatic cancer models. PRP targets different mechanisms than Revolution Medicines' recently approved daraxonrasib, which showed median overall survival of 13.2 months in clinical trials. Propanc plans to start a Phase 1b study in early 2027.